Srinagar, May 14 -- The injection, which takes just three to five minutes to administer, will benefit up to 15,000 patients each year and is approved for use across 15 types of cancer, including lung, bowel, kidney, bladder, oesophageal, skin, and head and neck cancers.

The move follows the approval of injectablenivolumab-also known by its brand nameOpdivo-by the Medicines and Healthcare products Regulatory Agency (MHRA). Previously, the drug was administered intravenously, a process that could take up to an hour. Now, with patients needing doses fortnightly or monthly, the new method is expected to save the NHS over a year's worth of treatment time annually.

"This innovation will make cancer treatment faster and more convenient for tho...